期刊文献+

帕金森病伴发焦虑的相关因素研究 被引量:3

Related Factors of Anxiety in Patients with Parkinson's Disease
原文传递
导出
摘要 目的:探讨帕金森病(PD)伴发焦虑的相关因素。方法:采用贝克焦虑量表(BAI)将入组60例PD患者分为焦虑和非焦虑组。记录两组患者基本情况及用药情况。选用帕金森病统一评价量表(UPDRS)和改良Hoehn&Yahr(H&Y)分期评价患者运动症状;选用蒙特利尔认知评估量表(MOCA)、贝克抑郁量表(BDI)、PD睡眠量表(PDSS)、Epworth嗜睡量表(ESS)和PD自主神经症状量表(SCOPA-AUT)评价患者非运动症状。结果:基本情况及运动症状方面,焦虑组与非焦虑组间差异无统计学意义。PD药物使用方面,焦虑组金刚烷胺的日剂量及左旋多巴等效日剂量(LEDD)低于非焦虑组(P<0.05)。非运动症状方面,焦虑组BDI、PDSS和SCOPA-AUT得分高于非焦虑组(P<0.05)。回归分析示,BAI得分与BDI、SCOPA-AUT得分呈正相关,与LEDD呈负相关。结论:抑郁和自主神经功能障碍是PD焦虑的危险因素,LEDD是PD焦虑的保护因素。 Objective:To explore the clinical related factors of anxiety in patients with Parkinson's disease(PD).Methods:According to the scores of Beck Anxiety Inventory(BAI),60 PD patients were divided into the anxiety group and the non-anxiety group.Demographic data and anti-Parkinson's medication usage of PD patients were collected.Unified Parkinson's Disease Rating Scale(UPDRS)and modified Hoehn and Yahr(HY)grade were used to evaluate the severity of the motor symptoms.Montreal Cognitive Assessment(MOCA),Beck Depression Inventory(BDI),the scale for outcomes in PD for autonomic symptoms(SCOPA-AUT),Parkinson's Disease Sleep Scale(PDSS)and Epworth Sleeping Scale(ESS)were used to evaluate the non-motor symptoms.Results:In terms of the demographic data and motor symptoms,there were no significant differences between the anxiety group and the non-anxiety group.In terms of anti-Parkinson's medication usage,amantadine usage and L-doppa equivalent daily dose(LEDD)of patients were lower than those of patients in the non-anxiety group(P〈0.05).Additionally,in terms of non-motor symptoms,the anxiety group had higher BDI,PDSS and SCOPA-AUT scores than those of patients in the non-anxiety group(P〈0.05).Multiple regression analysis demonstrated that BAI score was positive correlated with BDI score and SCOPA-AUT score,but was negativecorrelated with LEDD.Conclusion:Depression and autonomic dysfunction are the risk factors of anxiety in PD,and LEDD is the protective factor of anxiety in PD.
出处 《武汉大学学报(医学版)》 CAS 2016年第3期457-460,共4页 Medical Journal of Wuhan University
基金 湖北省卫计委重点项目(编号:WJ2015MA007) 武汉市科技局2015年应用基础研究计划项目(编号:2015060101010047)
关键词 焦虑 帕金森病 帕金森病药物 相关因素 Anxiety Parkinson's Disease Anti-Parkinson's Medication Factors
  • 相关文献

参考文献13

  • 1Nègre-Pagès L,Grandjean H,Lapeyre-Mestre M,et al.Anxious and depressive symptoms in Parkinson’s disease:the French cross-sectionnal DoPaMiP study[J].Mov Disord,2010,25(2):157-166.
  • 2Leentjens AF,Dujardin K,Marsh L,et al.Symptomatology and markers of anxiety disorders in Parkinson’s disease:a cross-sectional study[J].Mov Disord,2011,26(3):484-492.
  • 3Lees AJ,Hardy J,Revesz T.Parkinson’s disease[J].Lancet,2009,373(9 680):2 055-2 066.
  • 4Tomlinson CL,Stowe R,Patel S,et al.Systematic review of levodopa dose equivalency reporting in Parkinson’s disease[J].Mov Disord,2010,25(15):2 649-2 653.
  • 5Leentjens AF,Dujardin K,Marsh L,et al.Anxiety rating scales in Parkinson’s disease:a validation study of the Hamilton anxiety rating scale,the Beck anxiety inventory,and the hospital anxiety and depression scale[J].Mov Disord,2011,26(3):407-415.
  • 6Remy P,Doder M,Lees A,et al.Depression in Parkinson’s disease:loss of dopamine and noradrenaline innervation in the limbic system[J].Brain,2005,128(Prt):1 314-1 322.
  • 7Weintraub D,Newberg AB,Cary MS,et al.Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease[J].J Nucl Med,2005,46(2):227-232.
  • 8刘卓,孙莉,黄曦妍,曹辰杰,余舒扬,左丽君,杨雅琴,朴英善,张巍.帕金森病伴发焦虑与运动症状及非运动症状关系的研究[J].中华临床医师杂志(电子版),2012,6(2):12-17. 被引量:16
  • 9Rascol O,Perez-Lloret S,Ferreira JJ.New treatments for levodopa-induced motor complications[J].Mov Disord,2015,30(11):1 451-1 460.
  • 10McGarry A,Biglan K.Improvement of freezing of gait with amantadine in a patient with oculopharyngeal muscular dystrophy and Parkinsonism[J].Parkinsonism Relat Disord,2013,19(6):643-644.

二级参考文献15

  • 1朱慧颖,朱遂强.影响帕金森病患者生活质量的因素[J].中国康复,2007,22(3):169-171. 被引量:7
  • 2Remy P,Doder M,Lees A,et al.Depression in Parkinson's disease:loss of dopamine and noradrenaline innervation in the limbic system.Brain,2005,128:1314-1322.
  • 3Dissanayaka NN,Sellbach A,Matheson S,et al.Anxiety disorders in Parkinson's disease:prevalence and risk factors.Mov Disord,2010,25:838-845.
  • 4Kummer A,Cardoso F,Teixeira AL.Generalized anxiety disorder and the Hamilton Anxiety Rating Scale in Parkinson's disease.Arq Neuropsiquiatr,2010,68:495-501.
  • 5Czernecki V,Pillon B,Houeto JL,et al.Motivation,reward,and Parkinson's disease:influence of dopatherapy.Neuropsychologia,2002,40:2257-2267.
  • 6Minguez-Castellanos A,Chamorro CE,Escamilla-Sevilla F,et al.Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?a cohort study.Neurology,2007,68:2012-2018.
  • 7Probst A,Bloch A,Tolnay M.New insights into the pathology of Parkinson's disease:does the peripheral autonomic system become central?Eur J Neurol,2008,15:1-4.
  • 8Hobson JA,Pace-Schott EF.The cognitive neuroscience of sleep:neuronal systems,consciousness and learning.Nat Rev Neurosci,2002,3:679-693.
  • 9Quelhas R,Costa M.Anxiety,depression,and quality of life in Parkinson's disease.J Neuropsychiatry Clin Neurosci,2009,21:413-419.
  • 10Kulisevsky J,Pagonabarraga J,Pascual-Sedano B,et al.Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia.Mov Disord,2008,23:1889-1896.

共引文献15

同被引文献27

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部